Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study

Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: SPIN-HAND program
Sponsors:   Lady Davis Institute;   Hôpital Cochin
Not yet recruiting - verified May 2017

Riociguat in Scleroderma Associated Digital Ulcers

Conditions:   Scleroderma;   Digital Ulcers
Interventions:   Drug: Riociguat;   Drug: Placebo
Sponsors:   Dinesh Khanna, MD, MS;   Bayer
Recruiting - verified May 2017

Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma

Conditions:   Scleroderma;   Ssc
Intervention:   Other: Occupational therapy treatment
Sponsors:   University of Michigan;   University of Alabama at Birmingham
Recruiting - verified November 2016

The Effect of Ethanol Extract Physalis Angulata Linn in Scleroderma Patients With Standard Therapy

Condition:   Scleroderma
Interventions:   Other: Physalis angulata ethanol extract;   Other: Placebo
Sponsors:   Indonesia University;   Netherlands: Ministry of Health, Welfare and Sports
Recruiting - verified May 2017

Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers

Condition:   Digital Ulcer of Scleroderma
Interventions:   Drug: Diltiazem Gel 2%;   Drug: Nitroglycerin Ointment 2%;   Drug: Vaseline
Sponsors:   Mohammad Ali Nazarinia;   Shiraz University of Medical Sciences
Completed - verified March 2017

Duke Scleroderma Clinic Patient Registry

Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: Registry
Sponsor:   Duke University
Recruiting - verified April 2017

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Condition:   Scleroderma
Interventions:   Drug: BMS-986020;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Withdrawn - verified July 2016

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Condition:   Scleroderma, Systemic
Interventions:   Drug: Nintedanib;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2017

Taking Charge of Systemic Sclerosis

Condition:   Scleroderma
Interventions:   Other: Internet-based self-management program;   Other: Scleroderma book
Sponsors:   University of Michigan;   University of New Mexico;   Medical University of South Carolina;   Patient-Centered Outcomes Research Institute
Active, not recruiting - verified September 2016

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Conditions:   Scleroderma;   Interstitial Lung Disease
Intervention:   Drug: dabigatran etexilate
Sponsors:   Medical University of South Carolina;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2017

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Condition:   Scleroderma
Sponsor:   George Washington University
Recruiting - verified August 2016

Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial

Condition:   Systemic Scleroderma
Interventions:   Drug: C-82 Topical Gel, 1%;   Drug: C-82 Topical Gel, Placebo
Sponsor:   Prism Pharma Co., Ltd.
Completed - verified September 2016

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

Conditions:   Scleroderma;   Raynaud's Syndrome
Interventions:   Drug: Onabotulinumtoxin A;   Drug: sterile saline solution
Sponsors:   Johns Hopkins University;   Allergan
Completed - verified October 2016

Calcinosis in a Single-Center Scleroderma Population

Conditions:   Scleroderma;   Calcinosis
Sponsor:   Rutgers, The State University of New Jersey
Recruiting - verified November 2016

Scleroderma ARFI Imaging of the Skin

Condition:   Scleroderma
Intervention:   Device: ARFI-SVI Ultrasound
Sponsor:   University of Michigan
Completed - verified January 2017

IVIG Treatment in Systemic Sclerosis

Conditions:   Systemic Sclerosis;   Diffuse Scleroderma
Intervention:   Biological: Privigen
Sponsors:   Georgetown University;   CSL Behring
Active, not recruiting - verified January 2017

Scleroderma Registry & Repository at the Hospital for Special Surgery

Condition:   Scleroderma
Sponsor:   Hospital for Special Surgery, New York
Recruiting - verified March 2017

Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis

Condition:   Scleroderma
Intervention:   Drug: Campath
Sponsor:   Children's Hospital Los Angeles
Recruiting - verified August 2016

Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis

Condition:   Scleroderma
Intervention:   Drug: Lactobacillus
Sponsor:   University of Michigan
Withdrawn - verified December 2016

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Condition:   Scleroderma
Interventions:   Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
Sponsor:   Northwestern University
Recruiting - verified March 2017

Scleroderma Treatment With Autologous Transplant (STAT) Study

Condition:   Systemic Scleroderma
Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified January 2017

Effect of Bosentan in Scleroderma Renal Crisis

Condition:   Scleroderma Renal Crisis
Intervention:   Drug: Bosentan
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Actelion
Completed - verified October 2015

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2017

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis

Condition:   Systemic Sclerosis, Scleroderma
Intervention:   Drug: STI571
Sponsor:   Novartis Pharmaceuticals
Completed - verified March 2017

High Dose Cyclophosphamide for Treatment of Scleroderma

Condition:   Scleroderma
Intervention:   Drug: IV Cyclophosphamide
Sponsor:   Johns Hopkins University
Completed - verified August 2016

Refine Your Search Advanced Search